Table 1 Comparison of study variables between PD1 and PDL1 groups
From: Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma
Tumoral | Background | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
PD1 | p | PDL1 | p | PD1 | P | PDL1 | P | ||||||
Negative Frequency (%) | Positive Frequency (%) | Negative Frequency (%) | Positive Frequency (%) | Negative Frequency (%) | Positive Frequency (%) | Negative Frequency (%) | Positive Frequency (%) | ||||||
Gender | Male | 11 (50.0%) | 11 (50.0%) | 0.588a | 37 (92.5%) | 3 (7.5%) | 0.396a | 5 (22.7%) | 17 (77.3%) | 0.180a | 39 (97.5%) | 1 (2.5%) | 0.363a |
Female | 2 (66.7%) | 1 (33.3%) | 9 (100.0%) | 0 (0.0%) | 2 (66.7%) | 1 (33.3%) | 9 (90.0%) | 1 (10.0%) | |||||
Variant | Pleomorphic | 0 (0.0%) | 1 (100.0%) | 0.240a | 3 (100.0%) | 0 (0.0%) | 0.999b | 0 (0.0%) | 1 (100.0%) | 0.999a | (100.0%) | 0 (0.0%) | 0.999b |
Classic | 16 (59.3%) | 11 (40.7%) | 57 (95.0%) | 3 (5.0%) | 9 (33.3%) | 18 (66.7%) | 60 (96.8%) | 2 (3.2%) | |||||
Blastoid | - | - | 3 (100.0%) | 0 (0.0%) | - | - | 3 (100.0%) | 0 (0.0%) | |||||
Ki67 | < 30% | 1 (25.0%) | 3 (75.0%) | 0.999a | 7 (100.0%) | 0 (0.0%) | 0.523a | 1 (25.0%) | 3 (75.0%) | 0.999a | 7 (87.5%) | 1 (12.5%) | 0.999a |
≥ 30% | 4 (36.4%) | 7 (63.6%) | 12 (80.0%) | 3 (20.0%) | 2 (18.2%) | 9 (81.8%) | 14 (93.3%) | 1 (6.7%) | |||||